首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1416334

生技藥品合約開發市場報告：2030 年趨勢、預測與競爭分析

Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2024年01月29日 | 出版商:

Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

生技藥品合約發展趨勢及預測

到 2030 年，全球合約生技藥品開發市場預計將達到 409 億美元，2024 年至 2030 年複合年成長率為 11.5%。該市場的主要促進因素是製藥公司的藥物開發程序數量不斷增加、先進技術的採用不斷增加以及新興國家臨床試驗的有利環境。全球合約生技藥品開發市場的未來看起來充滿希望，腫瘤學、免疫學、心血管和血液學市場充滿機會。

生技藥品合約開發市場洞察

Lucintel 預測，由於擴大採用哺乳動物細胞來表達蛋白質，因此在預測期內，哺乳動物將繼續佔據更大的佔有率。透過開發具有正確轉譯後修飾的哺乳動物蛋白質以實現其天然結構，這提供了顯著的優勢。

腫瘤學將繼續成為該市場最大的細分市場，因為治療需求的不斷成長正在推動研發和外包的進一步投資。

由於研發投資不斷增加、臨床試驗需求不斷成長以及該地區領先公司的存在，預計北美在整個預測期內仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球合約生技藥品開發市場預計將達到 409 億美元。

Q2.市場成長預測是多少：

A2. 2024 年至 2030 年，全球生技藥品合約開發市場預計將以 11.5% 的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要促進因素是製藥公司增加藥物開發程序、增加先進技術的採用以及新興國家有利的臨床試驗環境。

Q4.市場的主要細分市場是：

A4.生技藥品合約開發市場的未來前景看好，在腫瘤學、免疫學、心血管和血液學市場中存在機會。

Q5.市場的主要企業是：

A5. 一些主要的生技藥品合約開發公司如下。

WuXi Biologics
Abzena
Fujifilm Diosynth Biotechnologies
KBI Biopharma
AGC Biologics
Thermo Fisher Scientific
Curia Global
Genscript
Bionova Scientific
BioXcellence

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，由於擴大採用哺乳動物細胞進行蛋白質表達，哺乳動物在預測期內將繼續佔據更大的佔有率。透過開發具有正確轉譯後修飾的哺乳動物蛋白質以實現其天然結構，這提供了顯著的優勢。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於研發投資增加、臨床試驗需求增加以及該地區領先公司的存在，預計北美仍將是整個預測期內最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

宏觀經濟趨勢（2018-2023）與預測（2024-2030）
全球生技藥品合約開發市場趨勢（2018-2023）與預測（2024-2030）
按來源分類的全球生技藥品開發市場
- 微生物
- 哺乳動物的
- 其他
按產品服務分類的全球生技藥品合約開發市場
- 細胞株開發
- 製程開發
- 其他
按疾病適應症分類的全球生技藥品合約開發市場
- 瘤
- 免疫疾病
- 心血管疾病
- 血液疾病
- 其他

第4章 2018-2030年區域市場趨勢及預測分析

按地區分類的全球生技藥品合約開發市場
北美生技藥品合約開發市場
歐洲合約生技藥品開發市場
亞太生技藥品合約開發市場
其他地區生技藥品合約開發市場

第5章競爭分析

產品系列分析
營運整合
波特五力分析

第6章成長機會與策略分析

成長機會分析
- 全球生技藥品合約開發市場成長機會（按來源）
- 全球生技藥品合約開發市場成長機會（依產品服務）
- 按疾病適應症分類的全球生技藥品合約開發市場的成長機會
- 按地區分類的全球生技藥品合約開發市場成長機會
全球生技藥品合約開發市場新趨勢
戰略分析
- 新產品開發
- 擴大全球合約生技藥品開發市場的能力
- 全球合約生技藥品開發市場的合併、收購和合資企業
- 認證和許可

第7章主要企業概況

WuXi Biologics
Abzena
Fujifilm Diosynth Biotechnologies
KBI Biopharma
AGC Biologics
Thermo Fisher Scientific
Curia Global
Genscript
Bionova Scientific
BioXcellence

簡介目錄

Biologics Contract Development Trends and Forecast

The future of the global biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets. The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030 with a CAGR of 11.5% from 2024 to 2030. The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

A more than 150-page report is developed to help in your business decisions.

Biologics Contract Development by Segment

The study includes a forecast for the global biologics contract development by source, product service, disease indication, and region.

Biologics Contract Development Market by Source [Shipment Analysis by Value from 2018 to 2030]:

Microbial
Mammalian
Others

Biologics Contract Development Market by Product Service [Shipment Analysis by Value from 2018 to 2030]:

Cell Line Development
Process Development
Others

Biologics Contract Development Market by Disease Indication [Shipment Analysis by Value from 2018 to 2030]:

Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others

Biologics Contract Development Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Biologics Contract Development Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biologics contract development companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biologics contract development companies profiled in this report include-

WuXi Biologics
Abzena
Fujifilm Diosynth Biotechnologies
KBI Biopharma
AGC Biologics
Thermo Fisher Scientific
Curia Global
Genscript
Bionova Scientific
BioXcellence

Biologics Contract Development Market Insights

Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Within this market, oncology will remain the largest segment due to growing demand for therapy, which encourages more investments in research and development and outsourcing.

North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Features of the Global Biologics Contract Development Market

Market Size Estimates: Biologics contract development market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Biologics contract development market size by source, product service, disease indication, and region in terms of value ($B).

Regional Analysis: Biologics contract development market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different sources, product services, disease indication, and regions for the biologics contract development market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biologics contract development market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the biologics contract development market size?

Answer: The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030.

Q2. What is the growth forecast for biologics contract development market?

Answer: The global biologics contract development market is expected to grow with a CAGR of 11.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the biologics contract development market?

Answer: The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

Q4. What are the major segments for biologics contract development market?

Answer: The future of the biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets.

Q5. Who are the key biologics contract development market companies?

Answer: Some of the key biologics contract development companies are as follows:

WuXi Biologics
Abzena
Fujifilm Diosynth Biotechnologies
KBI Biopharma
AGC Biologics
Thermo Fisher Scientific
Curia Global
Genscript
Bionova Scientific
BioXcellence

Q6. Which biologics contract development market segment will be the largest in future?

Answer: Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Q7. In biologics contract development market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the biologics contract development market by source (microbial, mammalian, and others), product service (cell line development, process development, and others), disease indication (oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Biologics Contract Development Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Biologics Contract Development Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Biologics Contract Development Market by Source
- 3.3.1: Microbial
- 3.3.2: Mammalian
- 3.3.3: Others
3.4: Global Biologics Contract Development Market by Product Service
- 3.4.1: Cell Line Development
- 3.4.2: Process Development
- 3.4.3: Others
3.5: Global Biologics Contract Development Market by Disease Indication
- 3.5.1: Oncology
- 3.5.2: Immunological Disorders
- 3.5.3: Cardiovascular Disorders
- 3.5.4: Hematological Disorders
- 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Biologics Contract Development Market by Region
4.2: North American Biologics Contract Development Market
- 4.2.2: North American Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
4.3: European Biologics Contract Development Market
- 4.3.1: European Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
- 4.3.2: European Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
4.4: APAC Biologics Contract Development Market
- 4.4.1: APAC Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
- 4.4.2: APAC Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
4.5: ROW Biologics Contract Development Market
- 4.5.1: ROW Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
- 4.5.2: ROW Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Biologics Contract Development Market by Source
- 6.1.2: Growth Opportunities for the Global Biologics Contract Development Market by Product Service
- 6.1.3: Growth Opportunities for the Global Biologics Contract Development Market by Disease Indication
- 6.1.4: Growth Opportunities for the Global Biologics Contract Development Market by Region
6.2: Emerging Trends in the Global Biologics Contract Development Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Biologics Contract Development Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biologics Contract Development Market
- 6.3.4: Certification and Licensing